The Effects Of Sevoflurane On The Progression And Cisplatinum Sensitivity Of Cervical Cancer Cells

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34. doi:10.3322/caac.2155130620402
   PubMed Web of Science ®Google Scholar
• Pfaendler KS, Tewari KS. Changing paradigms in the systemic treatment of advanced cervical cancer. Am J Obstet Gynecol. 2016;214(1):22–30. doi:10.1016/j.ajog.2015.07.02226212178
   PubMed Web of Science ®Google Scholar
• Tangjitgamol S, Katanyoo K, Laopaiboon M, Lumbiganon P, Manusirivithaya S, Supawattanabodee B. Adjuvant chemotherapy after concurrent chemoradiation for locally advanced cervical cancer. Cochrane Database Syst Rev. 2014;12:CD010401.
   Google Scholar
• Xiang M, Kidd EA. Benefit of cisplatin with definitive radiotherapy in older women with cervical cancer. J Natl Compr Canc Netw. 2019;17(8):969–975. doi:10.6004/jnccn.2019.728931390586
   PubMed Web of Science ®Google Scholar
• Liang H, Gu M, Yang C, Wang H, Wen X, Zhou Q. Sevoflurane inhibits invasion and migration of lung cancer cells by inactivating the p38 MAPK signaling pathway. J Anesth. 2012;26(3):381–392. doi:10.1007/s00540-011-1317-y22349744
   PubMed Web of Science ®Google Scholar
• Muller-Edenborn B, Roth-Z’graggen B, Bartnicka K, et al. Volatile anesthetics reduce invasion of colorectal cancer cells through down-regulation of matrix metalloproteinase-9. Anesthesiology. 2012;117(2):293–301. doi:10.1097/ALN.0b013e3182605df122739763
   PubMed Web of Science ®Google Scholar
• Ecimovic P, McHugh B, Murray D, Doran P, Buggy DJ. Effects of sevoflurane on breast cancer cell function in vitro. Anticancer Res. 2013;33(10):4255–4260.24122989
   PubMed Web of Science ®Google Scholar
• Brozovic G, Orsolic N, Knezevic F, et al. Evaluation of DNA damage in vivo induced by combined application of cisplatin and sevoflurane. Eur J Anaesthesiol. 2008;25(8):642–647. doi:10.1017/S026502150800417118400143
   PubMed Web of Science ®Google Scholar
• Ciechanowicz S, Zhao H, Chen Q, et al. Differential effects of sevoflurane on the metastatic potential and chemosensitivity of non-small-cell lung adenocarcinoma and renal cell carcinoma in vitro. Br J Anaesth. 2018;120(2):368–375. doi:10.1016/j.bja.2017.11.06629406185
   PubMed Web of Science ®Google Scholar
• Brozovic G, Orsolic N, Knezevic F, et al. Genotoxicity and cytotoxicity of cisplatin treatment combined with anaesthetics on EAT cells in vivo. Onkologie. 2009;32(6):337–343. doi:10.1159/00021806619521121
   PubMedGoogle Scholar
• Liang H, Wang H, Liu H, Wen X, Zhou Q, Yang C. The effects of combined treatment with sevoflurane and cisplatin on growth and invasion of human adenocarcinoma cell line A549. Biomed Pharmacother. 2013;67(6):503–509. doi:10.1016/j.biopha.2013.03.00523639227
   PubMed Web of Science ®Google Scholar
• Cibula D, Potter R, Planchamp F, et al. The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology guidelines for the management of patients with cervical cancer. Int J Gynecol Cancer. 2018;28(4):641–655. doi:10.1097/IGC.000000000000121629688967
   PubMed Web of Science ®Google Scholar
• Chemoradiotherapy for Cervical Cancer Meta-Analysis Collaboration. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. J Clin Oncol. 2008;26(35):5802–5812. doi:10.1200/JCO.2008.16.436819001332
   PubMed Web of Science ®Google Scholar
• Tohme S, Simmons RL, Tsung A. Surgery for cancer: a trigger for metastases. Cancer Res. 2017;77(7):1548–1552. doi:10.1158/0008-5472.CAN-16-153628330928
   PubMed Web of Science ®Google Scholar
• Buggy DJ, Hemmings HC. Special issue on anaesthesia and cancer. Br J Anaesth. 2014;113(Suppl 1):i1–i3. doi:10.1093/bja/aeu26125052940
   PubMed Web of Science ®Google Scholar
• Takekuma M, Kasamatsu Y, Kado N, et al. The issues regarding postoperative adjuvant therapy and prognostic risk factors for patients with stage I-II cervical cancer: a review. J Obstet Gynaecol Res. 2017;43(4):617–626. doi:10.1111/jog.1328228190285
   PubMed Web of Science ®Google Scholar
• Li L, Song X, Liu R, et al. Chemotherapy versus radiotherapy for FIGO stages IB1 and IIA1 cervical carcinoma patients with postoperative isolated deep stromal invasion: a retrospective study. BMC Cancer. 2016;16:403. doi:10.1186/s12885-016-2447-227387204
   PubMed Web of Science ®Google Scholar
• Jokic M, Vlasic I, Rinneburger M, et al. Ercc1 deficiency promotes tumorigenesis and increases cisplatin sensitivity in a Tp53 context-specific manner. Mol Cancer Res. 2016;14(11):1110–1123. doi:10.1158/1541-7786.MCR-16-009427514406
   PubMed Web of Science ®Google Scholar
• Hamilton G, Rath B. Pharmacogenetics of platinum-based chemotherapy in non-small cell lung cancer: predictive validity of polymorphisms of ERCC1. Expert Opin Drug Metab Toxicol. 2018;14(1):17–24. doi:10.1080/17425255.2018.141609529226731
   PubMed Web of Science ®Google Scholar
• Adan A, Kiraz Y, Baran Y. Cell proliferation and cytotoxicity assays. Curr Pharm Biotechnol. 2016;17(14):1213–1221. doi:10.2174/138920101766616080816051327604355
   PubMed Web of Science ®Google Scholar
• Beroukhim R, Mermel CH, Porter D, et al. The landscape of somatic copy-number alteration across human cancers. Nature. 2010;463(7283):899–905. doi:10.1038/nature0882220164920
   PubMed Web of Science ®Google Scholar
• Liu J, Yang L, Zhang J, et al. Knock-down of NDRG2 sensitizes cervical cancer Hela cells to cisplatin through suppressing Bcl-2 expression. BMC Cancer. 2012;12:370. doi:10.1186/1471-2407-12-37022920753
   PubMed Web of Science ®Google Scholar
• Chen X, Zhang Y, Shi Y, et al. MiR-873 acts as a novel sensitizer of glioma cells to cisplatin by targeting Bcl-2. Int J Oncol. 2015;47(4):1603–1611. doi:10.3892/ijo.2015.314326323558
   PubMed Web of Science ®Google Scholar
• Clucas J, Valderrama F. ERM proteins in cancer progression. J Cell Sci. 2014;127(Pt 2):267–275. doi:10.1242/jcs.13310824421310
   PubMed Web of Science ®Google Scholar
• Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 2010;141(1):52–67. doi:10.1016/j.cell.2010.03.01520371345
   PubMed Web of Science ®Google Scholar
• Ou-Yang M, Liu HR, Zhang Y, Zhu X, Yang Q. ERM stable knockdown by siRNA reduced in vitro migration and invasion of human SGC-7901 cells. Biochimie. 2011;93(5):954–961. doi:10.1016/j.biochi.2011.01.01721352885
   PubMed Web of Science ®Google Scholar
• Qin R, Cao L, Wang J, Liu J. Promoter methylation of ezrin and its impact on the incidence and prognosis of cervical cancer. Cell Physiol Biochem. 2018;50(1):277–287. doi:10.1159/00049400530282070
   PubMedGoogle Scholar
• Conseil G, Arama-Chayoth M, Tsfadia Y, Cole SPC. Structure-guided probing of the leukotriene C binding site in human multidrug resistance protein 1 (MRP1; ABCC1). FASEB J. 2019;16.
   PubMed Web of Science ®Google Scholar
• Abdallah HM, Al-Abd AM, El-Dine RS, El-Halawany AM. P-glycoprotein inhibitors of natural origin as potential tumor chemo-sensitizers: a review. J Adv Res. 2015;6(1):45–62. doi:10.1016/j.jare.2014.11.00825685543
   PubMed Web of Science ®Google Scholar
• Krishnakumar S, Mallikarjuna K, Desai N, et al. Multidrug resistant proteins: P-glycoprotein and lung resistance protein expression in retinoblastoma. Br J Ophthalmol. 2004;88(12):1521–1526. doi:10.1136/bjo.2004.04792815548804
   PubMed Web of Science ®Google Scholar
• Cole SP, Bhardwaj G, Gerlach JH, et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science. 1992;258(5088):1650–1654. doi:10.1126/science.13607041360704
   PubMed Web of Science ®Google Scholar
• Dalton WS, Scheper RJ. Lung resistance-related protein: determining its role in multidrug resistance. J Natl Cancer Inst. 1999;91(19):1604–1605. doi:10.1093/jnci/91.19.160410511581
   PubMedGoogle Scholar
• Bouhamyia L, Chantot-Bastaraud S, Zaidi S, et al. Immunolocalization and cell expression of lung resistance-related protein (LRP) in normal and tumoral human respiratory cells. J Histochem Cytochem. 2007;55(8):773–782. doi:10.1369/jhc.7A7176.200717438350
   PubMed Web of Science ®Google Scholar
• Mao ZP, Zhao LJ, Zhou SH, Liu MQ, Tan WF, Yao HT. Expression and significance of glucose transporter-1, P-glycoprotein, multidrug resistance-associated protein and glutathione S-transferase-pi in laryngeal carcinoma. Oncol Lett. 2015;9(2):806–810. doi:10.3892/ol.2014.275225621055
   PubMed Web of Science ®Google Scholar
• Li L, Luan Y, Wang G, et al. Development and characterization of five cell models for chemoresistance studies of human ovarian carcinoma. Int J Mol Med. 2004;14(2):257–264.15254775
   PubMed Web of Science ®Google Scholar
• Sugimoto H, Kawaraguchi Y, Nomura Y, et al. Exposure to 1 % sevoflurane for 6 hrs enhances proliferation of human colon cancer cells. Masui. 2015;64(4):357–361.26419095
   PubMedGoogle Scholar
• Nishiwada T, Kawaraguchi Y, Uemura K, Sugimoto H, Kawaguchi M. Effect of sevoflurane on human hepatocellular carcinoma HepG2 cells under conditions of high glucose and insulin. J Anesth. 2015;29(5):805–808. doi:10.1007/s00540-015-2025-925980989
   PubMed Web of Science ®Google Scholar